Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
Gainers
Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results.
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results.
G1 Therapeutics Announces Investigator Initiated Study Of Trilaciclib And Lurbinectedin In Patients With Extensive Stage Small Cell Lung Cancer
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it is supporting a Phase 2 investigator initiated study (ISS) of trilaciclib and lurbinectedin in patients
G1 Therapeutics Granted US Patent #11,395,821 Treatment of EGFR-driven cancer with fewer side effects
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=3594&f=G&l=50&d=PTXT&p=72&S1=20220726&OS=20220726&RS=20220726
COSELA (Trilaciclib Hydrochloride For Injection) Now Approved In China To Decrease The Incidence Of Chemotherapy-Induced Myelosuppression In Patients With Extensive-Stage Small Cell Lung Cancer
COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
RESEARCH
